Tag: Phase II Trial

Revolo Therapeutics

Revolo Biotherapeutics Announces Open Enrollment for Phase 2 Clinical Trial of...

Revolo Biotherapeutics announced it has activated clinical sites and opened enrollment in a Phase 2 clinical trial of its eosinophilic esophagitis therapy.
COUR Pharma Pipeline

COUR Announces First In-Human Dosing in Proof-of-Concept Trial of CNP-201 to...

CNP-201 is a nanoparticle containing peanut protein that aims to eliminate allergic responses.
Harmony Study

Alladapt Enrolling Participants for Clinical Study of OIT Therapy to Treat...

The study is still seeking participants 4-55 years of age.
COVID Vaccine Being Drawn

Michigan Medicine Helps Lead First National Study on How Highly Allergic...

First volunteer expected to receive an injection April 7 in Ann Arbor with results anticipated this summer.
Peanuts

Study: Few People with Peanut Allergy Tolerate Peanut after Stopping OIT

Continuing with a modest dose confers more protection, NIH-funded study finds.
Patient Undergoing SLIT

New Peanut Allergy Treatment Passes Phase 2 Trial, Shows Effectiveness and...

UNC School of Medicine researchers show that tiny under-the-tongue doses of peanut protein can offer safe and substantial protection against peanut allergy.
Eggs

Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for...

AR201 is the second development program that Aimmune is advancing to phase 2 using its Characterized Oral Desensitization ImmunoTherapy (CODIT™) platform.
Eggs

Aimmune to Begin Phase 2 Trials of Egg Allergy OIT Candidate

AR201 for Egg Allergy Phase 2 Initiation Planned for 2019.
AR101+dupilumab

Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...

Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
AR101+dupilumab

Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...

Study scheduled to commence next week.